Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin’s proprietary position in non-invasive frequency-based deep-brain neurostimulation

Patent covers transcranial alternating current dynamic frequency stimulation methods for anxiety, depression and insomnia — three large and underserved markets central to Nexalin’s HALO Clarity and NeuroCare strategies

HOUSTON, TX, June 04, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasive Deep Intracranial Frequency Stimulation (“DIFS”) of the brain, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,629,519, titled: “Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia.”

The newly issued patent is expected to provide U.S. intellectual property protection for Nexalin’s core dynamic frequency stimulation method through 2042, further strengthening the Company’s long-term competitive position in frequency-based deep-brain neurostimulation for anxiety, depression and insomnia.

The patent expands Nexalin’s growing intellectual property portfolio and reinforces the Company’s leadership in non-invasive, frequency-based deep-brain neurostimulation. The patent covers methods involving transcranial alternating current stimulation using dynamic frequency stimulation designed for anxiety, depression and insomnia — three conditions that collectively represent a significant global unmet medical need and are central to Nexalin’s broader clinical, regulatory and commercial strategy.

Nexalin believes the issuance of this patent and its existing patent portfolio are strategically important because they protect key elements of the Company’s proprietary approach to delivering dynamic frequency stimulation through non-invasive neuromodulation. Nexalin’s DIFS platform is designed to penetrate deeper brain structures associated with neuropsychiatric and neurological conditions. The Company’s proprietary DIFS treatment is designed to be administered and monitored through the Nexalin NeuroCare virtual clinic, which Nexalin believes represents a potential model for physician-supervised, drug-free, non-invasive mental health treatment for in-home use.

Schreibe Deinen Kommentar